Evidence map›Paper›PMID 34205261›Full record

ArticleInternational journal of molecular sciences2021

Early Effects of the Soluble Amyloid β

Carlos Alberto Castillo, Inmaculada Ballesteros-Yáñez, David Agustín León-Navarro, José Luis Albasanz, Mairena Martín

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Carlos Alberto CastilloDepartment of Nursing, Physiotherapy and Occupational Therapy, School of Physiotherapy and Nursing, University of Castilla-La Mancha, 45071 Toledo, Spain.ORCID 0000-0002-6313-5485
Inmaculada Ballesteros-YáñezRegional Center for Biomedical Research (CRIB), University of Castilla-La Mancha, 02071 Albacete, Spain.
David Agustín León-NavarroRegional Center for Biomedical Research (CRIB), University of Castilla-La Mancha, 02071 Albacete, Spain.
José Luis AlbasanzRegional Center for Biomedical Research (CRIB), University of Castilla-La Mancha, 02071 Albacete, Spain.ORCID 0000-0002-9927-5076
Mairena MartínRegional Center for Biomedical Research (CRIB), University of Castilla-La Mancha, 02071 Albacete, Spain.
University of Castilla-La Mancha · ES

Funding

Junta de Comunidades de Castilla-La Mancha SBPLY/19/180501/000251Ministerio de Ciencia e Innovación PID2019-109206GB-I00Universidad de Castilla-La Mancha 2020-GRIN-29108
6 · The paper itself

Abstract

The amyloid β peptide (Aβ) is a central player in the neuropathology of Alzheimer's disease (AD). The alteration of Aβ homeostasis may impact the fine-tuning of cell signaling from the very beginning of the disease, when amyloid plaque is not deposited yet. For this reason, primary culture of rat cortical neurons was exposed to Aβ

Indexed as

AdenosineAlzheimer DiseaseAmyloid beta-PeptidesAnimalsCerebral CortexFemaleNeuronsPeptide FragmentsPhospholipase C betaPregnancyRatsRats, WistarReceptor, Adenosine A1Receptor, Adenosine A2AReceptors, GlutamateReceptors, NeurotransmitterAdenosineAmyloid beta-Peptidesamyloid beta-protein (25-35)Peptide FragmentsPhospholipase C betaReceptor, Adenosine A1Receptor, Adenosine A2AReceptors, GlutamateReceptors, Neurotransmitteradenosine receptorsAlzheimer’s diseasebeta-amyloidmetabotropic glutamate receptors

Identifiers

PMID34205261
PMCPMC8234864
OpenAlexW3176950102

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.